Phenome-wide and genome-wide analyses of quality of life in schizophrenia by Pazoki, R et al.
Phenome-wide and genome-wide analyses of
quality of life in schizophrenia
Raha Pazoki*, Bochao Danae Lin*, Kristel R. van Eijk, Dick Schijven, Sonja de Zwarte,
GROUP Investigators†, Sinan Guloksuz and Jurjen J. Luykx
Background
Schizophrenia negatively affects quality of life (QoL). A handful of
variables from small studies have been reported to influence QoL
in patients with schizophrenia, but a study comprehensively
dissecting the genetic and non-genetic contributing factors to
QoL in these patients is currently lacking.
Aims
We adopted a hypothesis-generating approach to assess the
phenotypic and genotypic determinants of QoL in schizophrenia.
Method
The study population comprised 1119 patients with a psychotic
disorder, 1979 relatives and 586 healthy controls. Using linear
regression, we tested >100 independent demographic, cognitive
and clinical phenotypes for their associationwith QoL in patients.
We then performed genome-wide association analyses of QoL
and examined the association between polygenic risk scores for
schizophrenia, major depressive disorder and subjective well-
being and QoL.
Results
We found nine phenotypes to be significantly and independently
associated with QoL in patients, the most significant ones being
negative (β = −1.17; s.e. 0.05; P = 1 × 10–83; r2 = 38%), depressive
(β = −1.07; s.e. 0.05; P = 2 × 10–79; r2 = 36%) and emotional dis-
tress (β = −0.09; s.e. 0.01; P = 4 × 10–59, r2 = 25%) symptoms.
Schizophrenia and subjective well-being polygenic risk scores,
using various P-value thresholds, were significantly and con-
sistently associated with QoL (lowest association P-value = 6.8 ×
10–6). Several sensitivity analyses confirmed the results.
Conclusions
Various clinical phenotypes of schizophrenia, as well as schizo-
phrenia and subjective well-being polygenic risk scores, are
associated with QoL in patients with schizophrenia and their
relatives. These may be targeted by clinicians to more easily
identify vulnerable patients with schizophrenia for further social
and clinical interventions to improve their QoL.
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Patients with schizophrenia often experience adverse outcomes,
such as unemployment, frequent hospital admissions, long-term
dependency on healthcare and suicide. Premature mortality of
patients with schizophrenia has been reported to be 3.5 times1
greater than that of adults in the general population. The societal
costs of schizophrenia during a 12-month period have been esti-
mated to be as high as $890 million in the USA.2 All domains of
quality of life (QoL; physical, psychological and social) are severely
decreased in schizophrenia compared with healthy controls. QoL is
also increasingly becoming an important index for effectiveness of
treatment in schizophrenia.3 Several variables have been shown
to be associated with QoL among patients with schizophrenia,
such as age, gender, employment status, marital status, duration
of illness, body mass index, antipsychotic medication, number of
hospital admissions, level of knowledge about schizophrenia,
schizophrenia symptoms, coping mechanisms and comorbid
depression.4–12 However, a comprehensive, large-scale study that
uses in-depth phenotyping to investigate factors associated with
QoL in schizophrenia in a hypothesis-generating fashion is
lacking. In addition, to the best of our knowledge, the genetic under-
pinnings of QoL have not been investigated. Recently published
genome-wide association studies (GWASs) for schizophrenia13
and related traits, such as major depressive disorder (MDD)14
and subjective well-being,15 provide a timely opportunity to
investigate whether genetic mechanisms are at the root of QoL.
Knowledge of clinical and genetic contributing factors to QoL
in schizophrenia could inform clinicians to help identify vulnerable
patients and optimise secondary preventive care, thus reducing
the burden of disease. This could be achieved through optimisation
of treatment regimens (e.g. psychosocial interventions or
optimising psychopharmacological treatments) and targeting
clinical variables negatively influencing QoL. On a similar note,
insight into genetic factors contributing to QoL could contribute
to the early identification of vulnerable patients, and improve
their outcome.
Here, we used a hypothesis-generating approach and investi-
gated over 100 phenotypes to investigate factors related to QoL
among patients with schizophrenia. We additionally performed
genetic risk scoring in patients, relatives and healthy controls to
uncover associations between genetic susceptibility to schizophre-
nia, MDD and subjective well-being on the one hand, and QoL
on the other.
Method
Participants and study design
All procedures contributing to this work comply with the ethical
standards of the relevant national and institutional committees on
human experimentation and with the Helsinki Declaration of
1975, as revised in 2008. All procedures involving human
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subjects/patients were approved by the medical-ethical committee
of University Medical Center Utrecht. All participants provided
written informed consent for the study. The current study was per-
formed within a cohort of 3684 individuals, including 1119 patients
with schizophrenia, 1059 siblings, 920 parents and 586 controls
(Supplementary Appendix 2, Supplementary Fig. 1 available at
https://doi.org/10.1192/bjo.2020.140). We used two main subsets.
The first subset included patients only (n = 1119), to test non-
genetic contributing factors to QoL among patients with schizo-
phrenia. We chose this subset as we were interested in phenotypic
contributing factors to QoL in patients; however, other, larger
cohort studies may be more appropriate to probe contributing
factors to QoL in the general population. The second subset
included patients, relatives and controls with genetic data available
(n = 2265), to test genetic contributing factors to QoL.We chose this
subset to increase statistical power and as, intuitively, genetic con-
tributing factors to QoLmay (partly) overlap between patients, rela-
tives and controls. All participants were included from the Genetic
Risk and Outcome of Psychosis (GROUP) study,16 a multicentre,
large longitudinal study in The Netherlands and Belgium, investi-
gating various psychological and genetic variables among patients
with schizophrenia and their relatives. The study population was
followed up since 2004, in several mental healthcare institutions,
both in The Netherlands and Belgium. The detailed phenotypic
information of GROUP participants offers a unique and enriched
database.16 Psychosis-related and demographic variables that
were included in the analysis are presented in Supplementary
Appendix 1. These variables may be divided into symptoms and
experiences that were assessed with a range of (semi)-structured
scales, including drug use, family loading for psychiatric disorders,
social cognition, demographic variables, IQ, medication use data
and theory of mind scales. For the purpose of this study, we only
used the baseline assessments of the GROUP study (release 5.00),
as we were interested in factors contributing to QoL in schizophre-
nia apparent in its early disease stages (the first psychotic episode of
the GROUP participants had to occur within 10 years before this
first assessment). Supplementary Figure 1 shows a breakdown of
the study sample.
QoL assessment
QoL was assessed with the World Health Organization’s
WHOQOL-BREF, an abbreviated version of the World Health
Organization Quality of Life scale. The self-report WHOQOL-
BREF has been validated for a Dutch-speaking population of psy-
chiatric patients.16–18 Details of the Dutch WHOQOL-BREF are
described elsewhere.18 The WHOQOL-BREF scale includes 24
items covering four domains of QoL,18 namely physical health
(seven items), psychological (six items), social relations (three
items) and environment (eight items). The questionnaire addition-
ally provides a general estimate of QoL presented as five categories:
‘very bad’, ‘moderately bad’, ‘good nor bad’, ‘moderately good’ and
‘very good’. To reduce the number of QoL variables and create a
suitable variable for statistical analyses, we performed principal
component analysis to preferably identify one quantitative compo-
nent that best explained most of the variability in QoL domains,
without transformations, only in patients. Similar to a previously
published GWAS using principal component analysis to derive a
single phenotype,19 the percentage of variance accounted for by
the first unrotated principal component was computed. This prin-
cipal component was standardised for further analysis, explained
62.5% of the variability in our data and correlated well with all
WHOQOL-BREF domains (Supplementary Fig. 2), whereas the
other four components were correlated with only one of the
domains and showed minimal correlations with other domains of
QoL. We therefore used this first principal component for subse-
quent analyses.
Phenome-wide analyses
For the agnostic association analysis of QoL with the above
explained demographic and clinical phenotypes (Supplementary
Appendix 1), we used data from patients with complete data on
the QoL principal component, age, gender and study site (n = 925;
Supplementary Fig. 1). The number of independent variables was
calculated by testing two-by-two correlations between variables,
using non-parametric Spearman correlation. Variables with correl-
ation estimates >0.3 and statistically significant correlations
(P<0.05) were considered interdependent variables. This analysis
resulted in 105 independent variables. Generalised linear models
(GLM) adjusted for age, gender and study site were then used to
test the association of QoL with each of the clinical phenotypes.
The statistical significance threshold for this association analysis
was corrected for multiple testing with the Bonferroni correction
method, i.e. 4.76 × 10−04 (0.05 adjusted for 105 independent
tests).20 As sensitivity analysis, we calculated P-values for pheno-
type-QoL associations by using data with random samples of the
QoL variable, using 1000 iterations. We then calculated the prob-
ability that our observed P-values are driven by chance (empirical
P-values) by using the method of Davison and Hinkley,21 as
follows: (number of null P-values less than the observed + 1)/
(number of permutations + 1). For each trait-QoL association, we
declared statistical significance if none of the 1000 iterated
samples led to a permutated P-value less than the observed
P-value. This was equivalent to an empirical P-value of 0.001.
The variance in QoL explained by the phenotypes was calculated
with R2 values obtained from GLM. To then identify a set of
variables that were associated with QoL independent of one
another, we used the phenotypes that were associated with QoL
at P < 4.76 × 10−04 and selected the independent variables in a
backward stepwise regression model. As a sensitivity analysis, we
then regressed the most significantly associated phenotypes with
ordinal estimates of QoL as opposed to the first principal compo-
nent of QoL.
Genotyping, quality control and genome-wide
association analysis
Details of genotyping and GWAS of QoL can be found in
Supplementary Appendix 1. In brief, genotype data for 2812
GROUP participants were generated on a customised Illumina
Institute of Psychological Medicine and Clinical Neurology
chip array with 570 038 single-nucleotide polymorphisms (SNPs).
Quality control procedures were performed with PLINK, version
1.9 for Apple Mac (Harvard, USA; see https://zzz.bwh.harvard.
edu/plink/download.shtml).22 In total, 2505 individuals and
275 021 SNPs passed these abovementioned quality control steps.
After merging with the phenotype file, 2265 individuals were left
for genetic analyses (Supplementary Appendix 2, Supplementary
Fig. 1).
Additional SNPs were imputed on the Michigan server,23 using
the Haplotype Reference Consortium r1.1 2016 reference panel.
Although likely underpowered, for the benefit of possible future
meta-analyses and as a first exploratory approach we performed
linear mixed models association testing implemented in BOLT-
LMM (version 2.3) software for Apple Mac (Broad Institute,
USA; see https://alkesgroup.broadinstitute.org/BOLT-LMM/BOLT-
LMM_manual.html)24 to assess associations between SNPs and
QoL (Supplementary Appendix 1). BOLT-LMM corrects for con-
founding from population structure and cryptic relatedness. We used
the generally accepted association P-value threshold of P < 5 × 10−8
Pazoki et al
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for genome-wide significance. We report those findings in the
Supplementary Appendix 2 (Supplementary Figs. 7 and 8).
Polygenic risk score analyses of QoL
We used recent GWASs of schizophrenia,13 MDD14 and subjective
well-being15 for polygenic risk score (PRS) calculations.25 We chose
the PRSs of these disorders as they are strongly associated with QoL
in the general population.26–29 To verify that PRS of other traits were
indeed unlikely to be associated with QoL, the genetic correlations
between the primary BOLT- LMM GWAS summary statistics and
over 700 other disease traits were estimated with linkage disequilib-
rium score regression (http://ldsc.broadinstitute.org/).30 As a quality
control for PRS calculation, the SNPs that overlapped between the
summary statistics GWASs (training data-sets) and our data-set31
were extracted. Then, insertions or deletions, ambiguous SNPs,
SNPs with minor allele frequency <0.01 and imputation quality
(R2) < 0.8 in both training and target data-sets were excluded. To
account for complicated linkage disequilibrium structure of SNPs
in the genome, these SNPs were clumped in two rounds with
PLINK version 1.90b3z,32 according to previously established
methods:33,34 round 1 with the default parameters (physical distance
threshold 250 kb and linkage disequilibrium threshold (R2) of 0.5);
and round 2 with a physical distance threshold of 5000 kb and
linkage disequilibrium threshold (R2) of 0.2. Additionally, we
excluded all SNPs in genomic regions with strong or complex
linkage disequilibrium structures (e.g. the MHC region on chromo-
some 6; Supplementary Appendix 2, Supplementary Table 1). If only
odds ratios were reported in the summary statistics, they were log-
converted to β-values as effect sizes. To prevent possible study popu-
lation overlap affecting our results, all Dutch and Belgian individuals
had been excluded from the schizophrenia GWAS13 to allow
unbiased PRS computation.33 Sample overlap between GROUP
data withMDD and subjective well-being GWAS samples is unlikely
because all samples belong to different cohorts. To reassure that
there was indeed minimal to no sample overlap between GROUP
and MDD and subjective well-being samples, we checked the inter-
cepts of the genetic covariances from linkage disequilibrium score
regression analyses between the GROUP GWAS and MDD and
subjective well-being. Presence of sample overlapmodifies this inter-
cepts from zero,35 whereas in our study all intercepts turned out to
be close to zero (Supplementary Appendices 1 and 2, Supplementary
Table 2). We constructed PRSs based on schizophrenia risk alleles
weighted by their schizophrenia-increasing effect estimate, using
the Purcell et al method,22,36 i.e. using PLINK’s score function for
12 GWAS P-value thresholds (referred to as Pt from here
onward): 5 × 10−8, 5 × 10−7, 5 × 10−6, 5 × 10−5, 5 × 10−4, 5 × 10−3,
0.05, 0.1, 0.2, 0.3, 0.4 and 0.5. PRSs were calculated for 2505 patients,
relatives and controls (those remaining after quality control).
Genetic data and QoL variables were available for patients, relatives
and controls. We thus performed statistical analyses for the associ-
ation of PRSs with QoL in the whole sample after quality control
(N = 2265; Supplementary Appendix 2, Supplementary Fig. 1),
including patients, controls and family members. This approach
provided the opportunity to investigate genetic susceptibility of
these PRSs on QoL regardless of presence or absence of the
disease. We calculated explained variance and P-values for PRSs
on QoL in two stages. In the first stage, we analysed the effect of
age, gender and disease status on QoL to obtain residuals of this
model. Subsequently, we tested the association of the residuals of
the previous model with each of the various PRSs, using a linear
mixed model with family identification as random effect and the
first three genetic principal components as covariates. We addition-
ally included the most significantly associated PRSs from each
schizophrenia, MDD and well-being PRS group in one single
mixed model, to assess if these PRSs were statistically independent
of each other. We subsequently included negative, positive and
depressive symptoms as covariates (as these were previously
known to associate with QoL, which was also confirmed in the
current cohort), and PRSs in mixed models to assess the additional
explained variance of the three PRSs beyond clinical phenotypes.We
additionally performed sensitivity schizophrenia PRS analyses on
patients only, to assess whether we observed similar effects to the
combined set of patients, siblings and controls.
To claim significance for association analyses between PRS and
QoL, we Bonferroni-corrected the P-value formultiple testing (0.05/
3 = 0.016), which is likely to be conservative given the significant
and sizeable genetic correlations between the three PRS traits tested.
Results
Table 1 shows baseline characteristics of patients, relatives and con-
trols. In the GLM, 18 distinct variables were associated with QoL at
the Bonferroni significance threshold of 4.76 × 10−04 in patients
with schizophrenia (Fig. 1, Table 2 and Supplementary Appendix
2, Supplementary Fig. 3). In our permutation sensitivity analysis,
the same variables were significantly associated with QoL in add-
ition to one extra variable, educational degree (Table 2). The statis-
tically most significant phenotypes were negative (β =−1.17; s.e.
0.05, P = 1 × 10−83; r2 model = 38%), depressive (β =−1.07; s.e. 0.05;
P = 2 × 10−79; r2 model = 36%), emotional distress (β =−0.09; s.e.
0.01; P = 4 × 10−59; r2 model = 25%) and general psychopathology
(β = 0.81; s.e. 0.06; P = 3 × 10−40; r2 model = 17%) symptoms
(Table 2). In our regression model including these 18 variables,
nine remained independently associated with QoL (P<0.05),
explaining 58.55% of the variance in QoL. Ordered by decreasing
level of significance these are: negative symptoms, global assessment
of functioning, emotional distress, depressive symptoms, positive
symptoms, remission status, cannabis craving, number of unmet
needs and excitement (Table 2 and Supplementary Appendix 2,
Supplementary Table 3). In addition, there was a negative age
effect (β =−0.01; s.e. 0.003; P = 3 × 10−3) on QoL in the backward
stepwise model (Supplementary Appendix 2, Supplementary
Table 1 Baseline characteristics for patients, siblings and controls
Characteristics Patients (n = 1119) Controls (n = 586) Siblings (n = 1059) Parents (n = 920)
Age in years, mean (s.d.) 27.6 (7.9) 30.4 (10.6) 27.8 (8.3) 54.7 (6.7)
Gender, n (%) women 267 (23.9) 317 (54.1) 577 (54.5) 528 (57.4)
IQ, estimated, mean (s.d.) 95 (16.1) 109.7 (15.1) 102.8 (15.6) 103 (17.0)
Married/living together, n (%) 97 (9.3) 234 (41.1) 411 (40.2) 153 (70.8)
Years of education, mean (s.d.) 4 (2.1) 5.4 (1.8) 5.1 (2.1) 5.1 (2.3)
Nicotine use, mean number of cigarettes daily (s.d.) 11.7 (11) 3 (6.5) 4.9 (8.4) 4.3 (8.8)
Alcohol use, mean number of drinks per week (s.d.) 6.6 (12.1) 6.1 (8.5) 6.4 (8.6) 8.1 (10.6)
Current use of antipsychotics, n (%) 1062 (95) 0 (0) 0 (0) 2 (0.22)
Duration of illness (years), mean (s.d.) 4.2 (4) Not applicable Not applicable Not applicable
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Fig. 1 Results of the hypothesis-generating association analysis between clinical variables and QoL among patients with schizophrenia with
explained variance for QoL. Number of unmet needs was measured with the Camberwell Assessment of Need. Remission was measured with
the PANSS patient in remission tool. Suicide attempt was assessed with the composite file (a questionnaire with closed questions designed for
the Genetic Risk and Outcome of Psychosis study). Cannabis thoughts were defined as thoughts about cannabis use, measured with the
Obsessive Compulsive Drug Use Scale. Deficit syndrome was measured with the Schedule for the Deficit Syndrome. Obsessive–compulsive
symptoms total score was measured with the Yale–Brown Obsessive Compulsive Scale. Akathisia was measured with the Barnes akathisia
rating scale. PAS, Premorbid Adjustment Scale.
Table 2 The 18 distinct clinical variables associated with quality of life in the generalised linear model (n = 925 patients with schizophrenia); and one








Negative symptoms, points CAPE −1.17 0.05 0.38 1 × 10−83 0.001
Depressive symptoms, points CAPE −1.07 0.05 0.36 2 × 10−79 0.001
Emotional distress, points PANSS −0.09 0.01 0.25 4 × 10−59 0.001
General psychopathology symptoms, points PANSS −0.81 0.06 0.17 3 × 10−40 0.001
Global Assessment of Functioning (disabilities), pointsa GAF 0.03 0 0.15 2 × 10−34 0.001
Positive symptoms, points CAPE −0.05 0 0.13 1 × 10−23 0.001
Number of unmet needs, points CAN −0.11 0.01 0.10 3 × 10−23 0.001
Remission status, yes PANSS −0.56 0.07 0.07 8 × 10−17 0.001
Excitement, points PANSS −0.06 0.01 0.05 9 × 10−13 0.001
PAS total score PAS −0.25 0.04 0.04 5 × 10−11 0.001
Proportion of unmet needs CAN −0.69 0.11 0.04 2 × 10−9 0.001
Disorganisation, points PANSS −0.03 0.01 0.04 3 × 10−09 0.001
Obsessive–compulsive symptoms, yes Y-BOCS −0.43 0.08 0.03 4 × 10−08 0.001
Suicidal attempts (lifetime), yes Composite fileb −0.43 0.08 0.03 6 × 10−08 0.001
Cannabis craving, yes OC-DUS −0.31 0.06 0.04 1 × 10−07 0.001
Obsessive–compulsive total score OC-DUS −0.28 0.06 0.04 1 × 10−06 0.001
Deficit syndrome SDS −0.39 0.08 0.03 1.19 × 10−06 0.001
Akathisia BARS −0.15 0.04 0.01 3 × 10−04 0.001
Educational degree 0.06 0.02 0.01 5 × 10−04c 0.001
The clinical variables in bold were independently associated with quality of life in our stepwise regression model.
CAPE, Community Assessment of Psychic Experiences; PANSS, Positive and Negative Syndrome Scale; GAF, Global Assessment of Functioning; CAN, Camberwell Assessment of Need;
PAS, Premorbid Adjustment Scale; Y-BOCS, Yale–Brown Obsessive Compulsive Scale; OC-DUS, Obsessive-Compulsive Drug Use Scale; SDS, Schedule for the Deficit Syndrome; BARS,
Barnes Akathisia Rating Scale Global, a clinical assessment scale for akathisia.
a. Greater score indicates better functioning.
b. This scale contains a range of questions probing health.
c. In our permutation sensitivity analysis the same 18 variables remained associated, as well as one additional variable, educational degree.
Pazoki et al
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Table 3). Association analysis between ordinal estimates of
QoL showed similar results (Supplementary Appendix 2,
Supplementary Fig. 4). We additionally tested if any of these pheno-
types captured in the original World Health Organization question-
naire items showed associations with the phenotypes tested, and we
observed that the World Health Organization mobility item
explained 32%, 25%, 21% and 9% of the variances in depressive,
negative, positive and emotional symptoms, respectively. The rest
of the World Health Organization items each explained less than
8% variation in each of our statistically most significant phenotypes.
The variance in QoL explained by various PRSs (N = 2265) were
1.37% for schizophrenia, 1.37% for subjective well-being (Fig. 2) and
1.40% forMDD (Supplementary Appendix 2, Supplementary Fig. 5)
when using only genome-wide significant SNPs (Pt of 5 × 10−8).
The most significant associations between PRS and QoL were
observed for schizophrenia (Pt0.5; explained variance 1.58%, P =
7 × 10−6; Fig. 1), subjective well-being (Pt0.4; explained variance
1.82%, P = 0.004; Fig. 1) and MDD (Pt0.005; explained variance
1.62%, P = 0.01; Supplementary Appendix 2, Supplementary
Fig. 5). As a sensitivity analysis, we repeated the schizophrenia
PRS analysis on patients only (n = 633), and confirmed the same
pattern of association with QoL and the same Pt of 0.5 showing
most significant association results (Supplementary Appendix 2,
Supplementary Fig. 6). The SNP heritability of QoL was 13.19%
(s.e. 19.03). As expected, given the relatively low statistical power,
genetic correlation analysis in LDHub showed no statistically signi-
ficant results. Confirming our rationale for investigating the PRSs
chosen in the current study, genetic correlations of QoL with schizo-
phrenia13 and subjective well-being15 were the strongest, in the
expected direction (Supplementary Appendix 2, Supplementary
Table 2).
Schizophrenia Pt0.5 (P = 7 × 10
−6), MDD Pt0.005 (P = 0.01) and
subjective well-being Pt0.4 (P = 0.004) remained associated with
QoL independent of one another. After additional adjustment for
positive, negative and depressive symptoms, schizophrenia PRS
(Pt0.5; P = 0.002) and well-being PRS (Pt0.4; P = 0.04) remained
associated with QoL. Moreover, only schizophrenia and subjective
well-being PRSs were consistent with true polygenicity, explaining
a proportion of the variance in QoL, as may be appreciated by
increasing degrees of explained variances and increasing signifi-
cance levels with relaxing Pts (Fig. 2).
As stated above, all final clinical phenotypes included in our
regression model together explained 58.55% of the variability in
QoL. By adding schizophrenia Pt0.5, MDD Pt0.005 and subjective
well-being Pt0.4, the model explained 59.00% of the variability.
Discussion
Here, we identify non-genetic factors contributing to QoL among
patients suffering from schizophrenia. Our results show that
∼58% of variance in QoL may be explained by a range of demo-
graphic and clinical variables. We additionally demonstrate that
genetic predisposition to schizophrenia and subjective well-being
explain a (small) proportion of variability in QoL on top of clinical
variables. The novelty of our method lies in the use of hypothesis-
generating approaches to investigate a vast number of schizophre-
nia-associated genetic and non-genetic variables.
Most of the previous studies into QoL in schizophrenia had
small-to-moderate sample sizes,10,11,37 and have shown the associ-
ation of particularly negative and positive symptoms with QoL in





















































































































































































Fig. 2 Bar plot illustrating explained variance for association of polygenic risk scores of schizophrenia and subjective well-being with quality of
life. The figure illustrates the results with linear mixed models. Displayed are the number of single-nucleotide polymorphisms (N), the strengths
of the association results (–log10 P-value) and explained variances per Pt (P-value threshold). PRS, polygenic risk score.
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showed the effects of excitement,29 positive, negative and depres-
sive29 symptoms on QoL. The study by Domenech et al used
only clinical symptoms based on PANSS.29 We tested clinical
symptoms assessed with multiple internationally well-established
scales (e.g. Community Assessment of Psychic Experience, Positive
And Negative Syndrome Scale, Camberwell Assessment of Need)
and assessed a range of other phenotypic variables. Such rich phe-
notyping together with our large sample size allowed us to firmly
establish additional variables associated with QoL in schizophrenia
at increased statistical significance.Moreover, this approach allowed
us to weigh the effect of all variables in one model. In line with our
findings, a recent meta-analysis also found a substantial association
between depressive symptoms and personal recovery, a concept
related to QoL.38
Several of the variables we found to be associated with QoL in
schizophrenia had, to the best of our knowledge, not been reported,
such as disorganisation, obsessive–compulsive symptoms, suicidal
attempts, unmet needs, akathisia and cannabis craving. Although the
underlying mechanisms of this latter association are still unclear,
onemay speculate that cannabis craving constitutes a proxy for canna-
bis abstinence, which in turn may increase anxiety and thus reduce
psychological well-being. Alternatively, relatively high levels of canna-
bis dependencemay worsen symptoms and thus negatively affect QoL.
Genetic predisposition to schizophrenia captured by PRS
showed clear and persistent effects on QoL across all Pts. We also
observed moderate effects of polygenic susceptibility to subjective
well-being on QoL and no independent effects of genetic predispos-
ition to MDD on QoL in our cohort. Intriguingly, although statis-
tical power for PRSs derived from large GWAS cohorts is usually
relatively large, we found stronger associations for schizophrenia
PRS (GWAS N = 36 989 cases and 113 075 controls) than for
MDD PRS (GWAS N = 135 458 cases and 344 901 controls) and
subjective well-being PRS (GWAS N = 298 420). Possibly, genetic
architecture (relatively large SNP-based heritability for schizophre-
nia) and case–control ascertainment (relatively low numbers of
incorrectly diagnosed controls in schizophrenia) explain a stronger
association signal for schizophrenia PRS with QoL. Alternatively,
QoL in schizophrenia may simply be more genetically related to
schizophrenia than MDD, given how the nature of the disease
affects QoL in people who suffer from it. Hypothetically, MDD
and subjective well-being PRSs may be stronger determinants of
QoL in people who do not suffer from schizophrenia.
The current study benefits from a large sample size of a multi-
centre, prospective cohort study in The Netherlands, with compre-
hensive phenotypic assessments in individuals with schizophrenia.
The large sample size increases precision and reliability of our find-
ings. The combination of a large sample size and rich phenotyping
created a unique opportunity for a phenome-wide study to identify
contributing factors to QoL in schizophrenia. In addition, carefully
selected participants from several geographical locations restricted
the risk of selection bias. On the other hand, several limitations
should be borne in mind when interpreting our results. First, inter-
pretation of principal component-driven variables may not be intui-
tive. Here, we managed to show its feasibility and usefulness. We
reduced the number of variables of the four different domains of
QoL into one variable and were able to assess the impact of multiple
clinical and genetic determinants on this variable. Our results
showed consistency in terms of direction and magnitude of the
effect estimate when compared with ordinal domains of QoL
(Supplementary Fig. 3). Second, we are aware of the relatively low
power for genetic studies on a complex trait such as QoL, both in
our GWAS and linkage disequilibrium score regression analyses.
Our GWAS must therefore be regarded as a first exploratory
GWAS of QoL in patients with schizophrenia, their siblings and
healthy controls. Similarly, for linkage disequilibrium score
regression, we were underpowered to reveal clear genetic correla-
tions. Linkage disequilibrium score regression analysis was done
to explore possible genetic correlations with traits different from
the ones we investigated, and to investigate whether the trait with
most significant genetic correlation results was identical to the
trait with most significant PRS results, which indeed turned out to
be the case. Third, in the study population, about 97% of partici-
pants were White, which hampers generalisability to other ethnici-
ties. Fourth, given the uniqueness of our cohort and the lack of QoL
phenotyping data in other cohorts, we were unable to perform rep-
lication analyses. We encourage researchers to collect QoL and
genome-wide data to allow for such replication efforts. Finally,
our association analyses preclude us from drawing definite conclu-
sions about causality. Future, well-powered, prospective studies are
necessary to improve insight into possible causal mechanisms.
In conclusion, we highlight multiple clinical and genetic asso-
ciations with QoL that could be leveraged in daily care of patients
with schizophrenia to improve their QoL. The variables highlighted
in the current study could aid health professionals who interact with
patients with psychosis to more readily recognise the need for add-
itional interventions in patients showing a high burden of such phe-
notypes. For example, although high levels of positive and negative
symptoms are intuitively associated with QoL, disorganisation, can-
nabis craving and obsessive–compulsive symptoms are also import-
ant contributors, according to our analyses. Genetic risk scoring
may furthermore be used to optimise identification of those patients
with schizophrenia who are susceptible to low QoL, which in turn
may advance timely management for these vulnerable patients.
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